Essential diagnostic imaging agents to help identify disease and improve patient care
Improved diagnostic information for better patient management
Lantheus Holdings to Present at Upcoming Investor Conferences
Lantheus Holdings, Inc. Reports Third Quarter 2018 Financial Results
Lantheus Holdings to Host Third Quarter 2018 Earnings Conference Call on October 30, 2018 at 4:30 p.m. Eastern Time
The medical art of diagnosis is greatly facilitated by providing physicians access to diagnostic images with the greatest possible degree of definition, contrast and detailed information so that diagnostic certainty is increased and the number of uninterpretable or poorly interpretable images is reduced.
Lantheus Holdings to Present at Upcoming Investor Conferences
Lantheus Holdings, Inc. Reports Third Quarter 2018 Financial Results
Lantheus Holdings to Host Third Quarter 2018 Earnings Conference Call on October 30, 2018 at 4:30 p.m. Eastern Time
At Lantheus, we develop, manufacture and commercialize essential diagnostic imaging agents and products that help healthcare professionals identify disease and improve patient treatment and care.
Setting the standard for diagnostic quality, safety and commitment with the leading echocardiography contrast agent in North America.
We are developing next generation imaging agents to enhance the accuracy, reliability and safety of diagnostic imaging.
Setting the standard for diagnostic quality, safety and commitment with the leading echocardiography contrast agent in North America.